Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention
Authors:
- Victor H.T. ChenVCVictor H.T. Chen
- Prakash KrishnanPKPrakash Krishnan
- Paul LeePLPaul Lee
- Michael C. KimMKMichael C. Kim
- Angelica MaresAMAngelica Mares
- Javed SulemanJSJaved Suleman
- Pedro R. MorenoPMPedro R. Moreno
- Samin K. SharmaSSSamin K. Sharma
- 1 September 2008
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 156 (3) , 513-519
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)The American Journal of Cardiology, 2004
- Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial InfarctionNew England Journal of Medicine, 2002
- Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial InfarctionNew England Journal of Medicine, 2001
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialThe Lancet, 1999
- Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T LevelsNew England Journal of Medicine, 1999
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994